Skip to main
GLUE

GLUE Stock Forecast & Price Target

GLUE Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Monte Rosa Therapeutics Inc has demonstrated a substantial increase in enterprise value, moving from $2.22 billion to $3.28 billion, underscoring the potential within its pipeline of molecular glue degraders (MGDs) and reflecting investor confidence. Notably, the valuation for the NEK7 MGD MRT-8102 has surged to $1.16 billion based on promising interim Phase I GFORCE-1 data, highlighting the therapeutic promise of this candidate. Additionally, projected year-end 2026 cash has risen significantly to $505 million, indicating a stronger financial position that supports the company's ability to advance its innovative MGD programs.

Bears say

Monte Rosa Therapeutics Inc faces a challenging landscape characterized by potential setbacks that could negatively impact its financial outlook. The company's partnership prospects with major players like Roche and Novartis appear uncertain, evidenced by recent setbacks in regulatory approvals and increased risks of competition. Additionally, inherent risks in research and development, intellectual property, and management execution further contribute to concerns over Monte Rosa's ability to successfully navigate market challenges and secure future collaborations.

GLUE has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Monte Rosa Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Monte Rosa Therapeutics (GLUE) Forecast

Analysts have given GLUE a Buy based on their latest research and market trends.

According to 5 analysts, GLUE has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Monte Rosa Therapeutics (GLUE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.